Validation of the pretreatment derived neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: British Journal of Cancer, 110, 10, S. 2531-2536
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2014
- Ereignis
-
Veröffentlichung
- (wer)
-
Springer Science and Business Media LLC
- (wann)
-
2014
- Urheber
-
Dalpiaz, O.
Pichler, Martin
Mannweiler, S.
Martín Hernández, J. M.
Stojakovic, T.
Pummer, K.
Zigeuner, R.
Hutterer, G. C.
- DOI
-
10.1038/bjc.2014.180
- URN
-
urn:nbn:de:bvb:384-opus4-1036171
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:47 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dalpiaz, O.
- Pichler, Martin
- Mannweiler, S.
- Martín Hernández, J. M.
- Stojakovic, T.
- Pummer, K.
- Zigeuner, R.
- Hutterer, G. C.
- Universität Augsburg
- Springer Science and Business Media LLC
Entstanden
- 2014
Ähnliche Objekte (12)
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients
External validation of the derived neutrophil-tolymphocyte ratio as a prognostic factor in breast cancer patients [Poster]
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients
Best of ASCO 2022: bladder cancer
C-reactive protein and neutrophil/lymphocytes ratio: prognostic indicator for doubling overall survival prediction in pancreatic cancer patients
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients
External validation of the derived neutrophil-tolymphocyte ratio as a prognostic factor in breast cancer patients [Poster]
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients
Best of ASCO 2022: bladder cancer
C-reactive protein and neutrophil/lymphocytes ratio: prognostic indicator for doubling overall survival prediction in pancreatic cancer patients
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients
External validation of the derived neutrophil-tolymphocyte ratio as a prognostic factor in breast cancer patients [Poster]
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients
Best of ASCO 2022: bladder cancer
C-reactive protein and neutrophil/lymphocytes ratio: prognostic indicator for doubling overall survival prediction in pancreatic cancer patients